Mesoblast Limited

NASDAQ:MESO

Biotechnology

Healthcare
$11.64 +1.86%

+$0.26 today

Market cap
$1.51B
Beta
0.79
P/E (TTM)
-23.6
EPS (TTM)
-$0.06
52W Low $9.88High $21.50

Volume 0.13M

Average 0.21M

MESO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Mesoblast LimitedNASDAQ: MESO

Selling, General & Admin · Q4 FY2026 · quarter ended Jun 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q4 FY2026 selling, general & admin of $14.4M rose 30.2% year over year, behind the +45.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +1.3% a year.

Context

  • Selling, general & admin amounted to 45.6% of revenue in FY2026, down 182.9 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 3 analysts of $739.3M (+1241.0%) for the fiscal year ending Jun 2027, a step up from the +40.3% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$14.4M+0.0% QoQ
Last fiscal yearJun 2026
$55.13M+40.3% YoY
LTMJun 2026
$57.35M+45.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.2%+698.1%+667.9 pp
1 year+40.3%+1241.0%+1200.7 pp
3-year CAGR+1.3%+266.5%+265.2 pp
5-year CAGR+146.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2026
55.13M USD
Year-over-year change
+40.3%
4-year CAGR
-1.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How MESO compares with its peers on the latest reported figures

  • MESO's LTM Jun 2026 selling, general & admin of $57.35M is the 2nd highest of the 6 companies compared; the peer median is $42.34M.
  • Its year-over-year change of +45.9% is the 2nd highest of 6, against a peer median of +3.6%.
  • Selling, general & admin amounts to 47.7% of revenue for MESO, versus a peer median of 159.8%.
MESO Competitors Peer median
Selling, General & Admin for MESO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$357.49M +10.5%+25.2%26.3%
MESOMesoblast LimitedLTM Jun 2026$57.35M +45.9%+1.3%47.7%
CELUCelularity Inc.LTM Dec 2025$51.27M -12.6%-8.1%193.1%
FATEFate Therapeutics, Inc.LTM Mar 2026$42.34M -49.3%-18.0%670.4%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$26.76M +58.7%+29.7%—
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$18.69M +3.6%-6.4%126.4%
Peer median (excluding MESO) $42.34M+3.6%-6.4%159.8%

Competitors are the stored peer set for MESO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue10.21M7.5M5.9M17.2M120.79M
Cost of Revenue63.57M54.92M41.07M5.13M19.21M
Gross Profit(53.36M)(47.42M)(35.17M)12.07M101.58M
Gross Margin-522.6%-632.2%-595.9%70.2%84.1%
Research & Development32.82M27.19M25.35M34.81M97.94M
Selling, General & Admin57.97M53.11M23.63M39.31M55.13M
Operating Expenses90.79M76.79M48.98M74.51M153.08M
Depreciation & Amortization4.38M4.11M1.9M6.4M8.62M
EBITDA(76.57M)(58.55M)(56.08M)(73.66M)(42.88M)
EBITDA Margin-749.9%-780.6%-950.1%-428.3%-35.5%
Operating Income(80.57M)(69.29M)(84.15M)(62.44M)(51.5M)
Operating Margin-789.1%-923.7%-1425.7%-363.1%-42.6%
Interest Income0831K1.82M3.55M3.93M
Interest Expense17.29M19.44M20.66M22.93M23.95M
Other Income / Expenses(10.48M)(12.81M)(4M)(39.37M)(5.64M)
Income Before Tax(91.59M)(82.1M)(88.15M)(101.81M)(57.14M)
Pre-Tax Margin-896.9%-1094.5%-1493.5%-592.0%-47.3%
Income Tax Expense(239K)(212K)(191K)330K615.74K
Net Income(91.35M)(81.89M)(87.96M)(102.14M)(57.76M)
Net Margin-894.6%-1091.7%-1490.3%-593.9%-47.8%
EPS (Basic)(1.30)(0.98)(0.89)(0.84)(0.45)
EPS (Diluted)(1.30)(0.98)(0.89)(0.84)(0.45)
Weighted Avg Shares68.27M83.77M98.67M120.78M129.49M
Weighted Avg Shares (Diluted)68.29M83.93M98.67M120.78M129.49M

Mesoblast Limited

NASDAQ:MESO

Intrinsic Alpha fair value

Locked

Current Price

$11.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.